RNAC
Cartesian Therapeutics Inc.
$8.17
+$0.06(+0.74%)
34
Overall
40
Value
10
Tech
52
Quality
Market Cap
$216.34M
Volume
33.56K
52W Range
$7.88 - $26.50
Target Price
$36.43
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||||
| Total Revenue | $8.1M | $207.0K | $903.0K | $6.7M | $16.6M | $85.1M | $110.8M | $26.0M | $38.3M | ||
| Total Revenue | $8.1M | $207.0K | $903.0K | $6.7M | $16.6M | $85.1M | $110.8M | $26.0M | $38.9M | ||
| GROSS PROFIT | |||||||||||
| Gross Profit | $8.1M | $207.0K | $903.0K | $6.7M | $16.6M | $85.1M | $110.8M | $26.0M | $38.9M | ||
| OPERATING EXPENSES | |||||||||||
| Operating Expenses | $-42.8M | $-64.0M | $-65.9M | $59.1M | $73.4M | $89.7M | $96.2M | $112.4M | $82.8M | ||
| Research & Development | $29.7M | $45.2M | $47.7M | $42.7M | $54.5M | $68.7M | $72.4M | $71.3M | $45.1M | ||
| Research Expense | $29.7M | $45.2M | $47.7M | $42.7M | $54.5M | $68.7M | $72.4M | $71.3M | $45.1M | ||
| Selling, General & Administrative | $13.1M | $18.8M | $18.2M | $16.4M | $18.9M | $20.9M | $23.9M | $40.5M | $30.1M | ||
| General & Administrative Expenses | $13.1M | $18.8M | $18.2M | $16.4M | $18.9M | $20.9M | $23.9M | $40.5M | $30.1M | ||
| Salaries & Wages | $-2.1M | $-4.1M | $-5.7M | -- | -- | -- | -- | $25.8M | $6.6M | ||
| Depreciation & Amortization | $-800.0K | $-800.0K | $-1.0M | $700.0K | $600.0K | $600.0K | $700.0K | $700.0K | $1.2M | ||
| Depreciation & Amortization | $-800.0K | $-800.0K | $-1.0M | $700.0K | $600.0K | $600.0K | $700.0K | $700.0K | $1.2M | ||
| Amortization | -- | -- | -- | -- | $100.0K | $700.0K | $600.0K | $48.2M | $48.2M | ||
| Other Operating Expenses | $-42.8M | $-64.0M | $-65.9M | $59.1M | $73.4M | $89.7M | $96.2M | $112.4M | $82.8M | ||
| OPERATING INCOME | |||||||||||
| Operating income | $-34.7M | $-63.8M | $-65.0M | $-52.5M | $-56.8M | $-4.6M | $14.5M | $-86.4M | $-43.9M | ||
| EBITDA | $-34.0M | $-63.1M | $-62.9M | $-52.0M | $-66.6M | $-5.6M | $40.0M | $-234.0M | $-73.5M | ||
| NON-OPERATING ITEMS | |||||||||||
| Interest Expense (Non-Operating) | $1.3M | $1.2M | $1.5M | $1.5M | $1.6M | $2.8M | $3.0M | $2.1M | -- | ||
| Intinc | -- | -- | -- | -- | -- | -- | -- | $5.0M | $7.4M | ||
| Net Non-Operating Interest Income/Expense | $-1.0M | $-589.0K | $-444.0K | $-1.5M | $-1.6M | $-2.8M | $-3.0M | $5.0M | $7.4M | ||
| Gain on Sale of Securities | -- | -- | -- | $834.0K | $260.0K | $44.0K | $2.1M | $-149.6M | $-6.9M | ||
| Other Income/Expense | $-4.0K | $825.0K | $-10.0K | $1.3M | $10.6M | $2.3M | $23.3M | $136.2M | $3.1M | ||
| Other Special Charges | $4.0K | $-825.0K | $10.0K | $-2.2M | $-10.8M | $-2.3M | $21.2M | $13.4M | $3.8M | ||
| SPECIAL ITEMS | |||||||||||
| Restructring And Mn A Income | -- | -- | -- | -- | -- | -- | $-29.6M | $232.3M | $798.0K | ||
| Special Income Charges | -- | -- | -- | -- | -- | -- | $29.6M | $-710.0K | $-7.6M | ||
| Impairment of Capital Assets | -- | -- | -- | -- | -- | -- | -- | $710.0K | $7.6M | ||
| PRE-TAX INCOME | |||||||||||
| EBIT | $-35.0M | $-64.1M | $-63.8M | $-53.8M | $-67.3M | $-6.9M | $37.8M | $-236.6M | $-77.1M | ||
| Pre-Tax Income | $-36.2M | $-65.3M | $-65.3M | $-55.4M | $-68.9M | $-9.7M | $34.8M | $-238.7M | $-77.1M | ||
| INCOME TAX | |||||||||||
| Tax Provision | -- | -- | -- | -- | -- | $16.0M | $-609.0K | $-19.0M | $287.0K | ||
| NET INCOME | |||||||||||
| Net Income | $-36.2M | $-65.3M | $-65.3M | $-55.4M | $-68.9M | $-25.7M | $35.4M | $-219.7M | $-77.4M | ||
| Net Income (Continuing Operations) | $-36.2M | $-65.3M | $-65.3M | $-55.4M | $-68.9M | $-25.7M | $35.4M | $-219.7M | $-77.4M | ||
| Net Income (Discontinued Operations) | $-36.2M | $-65.3M | $-65.3M | $-55.4M | $-68.9M | $-25.7M | $35.4M | $-219.7M | $-77.4M | ||
| Net Income (Common Stockholders) | $-40.8M | $-65.3M | $-65.3M | $-55.4M | $-68.9M | $-25.7M | $35.4M | $-219.7M | $-77.4M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | $-68.0M | ||
| TOTALS | |||||||||||
| Total Expenses | $-42.8M | $-64.0M | $-65.9M | $59.1M | $73.4M | $89.7M | $96.2M | $112.4M | $82.8M | ||
| SHARE & EPS DATA | |||||||||||
| Average Shares Outstanding | $10.5M | $20.4M | $22.4M | $45.5M | $101.2M | $114.3M | $4.8M | $5.2M | $17.3M | ||
| Average Shares Outstanding (Diluted) | $9.3M | $20.4M | $22.4M | $45.5M | -- | $114.3M | $4.9M | $5.2M | $17.4M | ||
| Shares Outstanding | $18.5M | $22.3M | $44.7M | $86.4M | $3.7M | $4.1M | $5.1M | $5.4M | $25.9M | ||
| Basic EPS | -- | -- | -- | $-1.22 | $-0.68 | $-0.22 | $7.2 | $-49.8 | $-4.48 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | $-1.22 | $-0.68 | $-0.22 | $7.2 | $-49.8 | $-4.48 | ||
| Diluted EPS | $-3.89 | $-3.2 | $-2.92 | $-1.22 | $-0.68 | $-0.22 | $3 | $-49.8 | $-4.49 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | $-0.22 | $3 | $-49.8 | $-4.49 | ||
| OTHER METRICS | |||||||||||
| Accretion On Preferred Stock | $4.6M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $13.1M | $18.8M | $18.2M | $16.4M | $18.9M | $20.9M | $23.9M | $40.5M | $30.1M | ||
| Otherunder Preferred Stock Dividend | $4.6M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Preferred Stock Dividends | $4.6M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $13.1M | $18.8M | $18.2M | -- | -- | -- | -- | -- | -- | ||
| Restruct | -- | -- | -- | -- | -- | -- | $-29.6M | $232.3M | $798.0K | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RNAC | $8.17 | +0.7% | 33.56K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Cartesian Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW